Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral-Induced Cure of Hepatitis C Virus Infection.

• Tác giả: Yu-Ping Chang, Chi-Yi Chen, Pei-Jer Chen, Shang-Chin Huang, Jia-Horng Kao, Wei-Yu Kao, Fu-Jen Lee, Ji-Yuh Lee, Chih-Lin Lin, Chen-Hua Liu, Chun-Jen Liu, Cheng-Yuan Peng, Yu-Lueng Shih, Tung-Hung Su, Ming-Chang Tsai, Tai-Chung Tseng, Sheng-Shun Yang
• Ngôn ngữ: eng
• Thông tin xuất bản: England : Alimentary pharmacology & therapeutics , 2025
• Bộ sưu tập: NCBI
• ID: 239077

Tóm tắt

 BACKGROUND: Data regarding the risk of incident type 2 diabetes (T2D) and prediabetes among patients with hepatitis C virus (HCV) achieving direct-acting antivirals (DAAs)-induced sustained virologic response (SVR METHODS: A total of 1079 patients, including 589 with normoglycemia and 490 with prediabetes, who underwent biannual fasting glucose and glycosylated haemoglobin (HbA1c) assessment for a median post-SVR RESULTS: The cIRs of T2D and prediabetes were 1.18 and 8.99 per 100 person-years of follow-up (PYFU), respectively. Additionally, the ASIRs of T2D and prediabetes were 1.09 (95% CI: 0.76-1.53) and 8.47 (95% CI: 7.23-9.90) per 100 PYFU. Prediabetes (adjusted hazard ratio [aHR]: 4.71
  95% confidence interval (CI): 2.55-8.70, p <
  0.001), body mass index (BMI) per kg/m CONCLUSION: The incidence rates of T2D and prediabetes remain substantial among patients after HCV eradication. Lifestyle modification, drug therapy and regular monitoring of glycemic status are crucial for patients at risk of developing T2D and prediabetes following HCV clearance.